crohn's

Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.

Brazikumab (AMG 139), a human IgG2 monoclonal antibody, selectively targets the p19 subunit of IL-23 with a dissociation constant (K D) of 0.138 nM, indicating high affinity for human IL-23. It is employed in Crohn's disease research [1].

Certolizumab pegol (Certolizumab) is a recombinant, humanized monoclonal antibody fragment that has been modified with polyethylene glycol (PEG), which selectively targets and neutralizes tumor necrosis factor-alpha (TNF-α). This compound is utilized in the research of rheumatoid arthritis and Crohn's disease [1] [2].

Onercept, a recombinant soluble form of the human tumor necrosis factor-alpha (TNF-α) p55 receptor, is utilized in the study of Crohn's disease [1].

Ravagalimab (ABBV-323), a CD40 antagonist with an EC50 of 3.7 nM, is utilized in the research of Crohn's disease [1].

Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis.

Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody that targets TNFSF15/TL1A, with potential applications in researching various inflammatory and fibrotic diseases, including Crohn's Disease (CD) [1] [2].

Visilizumab, a humanized IgG2 monoclonal antibody with low Fc receptor binding affinity, targets the CD3 epsilon (CD3ε) subunit. It is utilized in research related to ulcerative colitis and Crohn's disease [1].

Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Duvakitug, a humanized IgG1-λ2 monoclonal antibody, targets TNFSF15/TL1A and is primarily expressed in CHOK1SV cells with endogenous glutamine synthetase (GS) activity. It has applications in the research of Crohn's Disease (CD) [1] [2].

Eldelumab (BMS-936557) is a humanized anti-IP-10 IgG type 1 monoclonal antibody with inhibitory activity against CXCL10.Eldelumab has anti-inflammatory activity and selectively binds to CXCL10 and can be used in the study of rheumatoid arthritis, ulcerative colitis, and Crohn's disease.